Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients

Radiotherapy and Oncology

Volumn 83, Issue 3, 2007, Pages 389-397

  Nordsmark, Marianne ^a,b   Eriksen, Jesper Grau ^a   Gebski, Val ^c   Alsner, Jan ^a   Horsman, Michael R ^a   Overgaard, Jens ^a  

^a Department of Experimental Clinical Oncology ^*  (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CA9; Head and neck cancer; HIF 1 ; Osteopontin; Prognostic marker; Radiotherapy; Tumour hypoxia

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER STAGING; CONTROLLED STUDY; ELECTRODE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPOXIA; MAJOR CLINICAL STUDY; MALE; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL HYPOXIA; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NIMORAZOLE; OSTEOPONTIN; OXYGEN; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 34250166555     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.04.021     Document Type: Article

References (40)

1. Gray H.L., Conger A.D., Ebert M., Hornsey S., and Scott O.C.A. The concentration of oxygen dissolved in the tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953) 638-648
2. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Sem Rad Oncol 6 (1996) 10-21
3. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46 (1998) 135-146
4. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
5. Kaufman B., Scharf O., Arbeit J., et al. Proceedings of the oxygen homeostasis/hypoxia meeting. Cancer Res 64 (2004) 3350-3356
6. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
7. Vaupel P., Kallinowski F., and Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49 (1989) 6449-6465
8. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
9. Le Q.T., Sutphin P.D., Raychaudhuri S., et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9 (2003) 59-67
10. Hwang S.M., Wilson P.D., Laskin J.D., and Denhardt D.T. Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: contrasting responses to hypoxia and reoxygenation. J Cell Physiol 160 (1994) 61-68
11. Sodhi C.P., Phadke S.A., Batlle D., and Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: potentiation by high glucose. Diabetes 50 (2001) 1482-1490
12. Sorensen B.S., Hao J., Overgaard J., et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 76 (2005) 187-193
13. Sørensen B.S., Alsner J., Overgaard J., and Horsman M.R. Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. Radiother Oncol 83 (2007) 262-266
14. Lukacova S., Khalil A.A., Overgaard J., Alsner J., and Horsman M.R. Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum. Int J Radiat Biol 81 (2006) 937-944
15. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., and Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
16. Semenza G.L., Roth P.H., Fang H.M., and Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269 (1994) 23757-23763
17. Yu A.Y., Frid M.G., Shimoda L.A., Wiener C.M., Stenmark K., and Semenza G.L. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 275 (1998) L818-L826
18. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8 (2002) S62-S67
19. Semenza G.L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5 (2004) 405-406
20. Quintero M., Mackenzie N., and Brennan P.A. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol 30 (2004) 465-468
21. Eriksen J.G., and Horsman M.R. Tumour hypoxia - a characteristic feature with a complex molecular background. Radiother Oncol 81 (2006) 119-121
22. Bussink J., Kaanders J.H., and van der Kogel A.J. Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiother Oncol 82 (2007) 10-17
23. Nordsmark M., and Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 43 (2004) 396-403
24. In: Hermanek P., and Sobin L.H. (Eds). TNM classification of malignant tumours (1987), Springer-Verlag, Berlin, Heidelberg, New York p. 13-33
25. Nordsmark M., Bentzen S.M., and Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of intra- and inter-tumour heterogeneity. Acta Oncol 33 (1994) 383-389
26. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61 (2001) 2911-2916
27. Fine J.P., and Gray R.J. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509
28. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
29. Eriksen J.G., Overgaard J., and on behalf of the Danish Head and Neck Cancer Study Group (DAHANCA). Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study. Radiother Oncol 83 (2007) 383-388
30. Hill R.P. Targeted treatment: insights from studies of osteopontin and hypoxia. Lancet Oncol 6 (2005) 733-734
31. Becker A., Hansgen G., Bloching M., Weigel C., Lautenschlager C., and Dunst J. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 42 (1998) 35-41
32. Zhu Y., Denhardt D.T., Cao H., et al. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24 (2005) 6555-6563
33. Hampel D.J., Sansome C., Romanov V.I., Kowalski A.J., Denhardt D.T., and Goligorsky M.S. Osteopontin traffic in hypoxic renal epithelial cells. Nephron Exp Nephrol 94 (2003) e66-e76
34. Petrik D., Lavori P.W., Cao H., et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 24 (2006) 5291-5297
35. Vordermark D., Said H.M., Katzer A., et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6 (2006) 207
36. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N Engl J Med 353 (2005) 2477-2490
37. Jankovic B., quino-Parsons C., Raleigh J.A., et al. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom 70 (2006) 45-55
38. Bache M., Reddemann R., Said H.M., et al. Immunohistochemical detection of Osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys (2006)
39. Jonathan R.A., Wijffels K.I., Peeters W., et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79 (2006) 288-297
40. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721